BMS-354825: a novel drug with potential for the treatment of imatinib-resistant chronic myeloid leukaemia (Q36040892)

11 August 2017

1 reference

title

BMS-354825: a novel drug with potential for the treatment of imatinib-resistant chronic myeloid leukaemia (English)

1 reference

11 August 2017

1 reference

1 reference

Sheila A Doggrell

1

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 January 2005

1 reference

Expert Opinion on Investigational Drugs

11 August 2017

published in

1 reference

11 August 2017

volume

14

1 reference

11 August 2017

issue

1

1 reference

11 August 2017

page(s)

89-91

1 reference

Overriding imatinib resistance with a novel ABL kinase inhibitor

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.89

Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.89

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.89

Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.89

Long-term survival estimates for imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.89

SRCircumventing imatinib resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.89

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.14.1.89

21 January 2018

Identifiers

DOI

10.1517/13543784.14.1.89

1 reference

release_24mkejwqprfthbx6p3khrwpgui

11 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/24mkejwqprfthbx6p3khrwpgui

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference